Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano‐Immunoadjuvant

Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano‐Immunoadjuvant

Abstract Immunotherapy with toll like receptor 9 (TLR9) agonist CpG ODN offers an emergent strategy to treat life‐threatening malignant glioma. CpG is typically applied invasively by intracranial and intrathecal administration which induces not only poor compliance and lessened potency but also poss...

Full description

Bibliographic Details
Main Authors: Jingjing Wei, Di Wu, Songsong Zhao, Yu Shao, Yifeng Xia, Dawei Ni, Xinyun Qiu, Jinping Zhang, Jian Chen, Fenghua Meng, Zhiyuan Zhong
Format: Article
Language:English
Published: Wiley 2022-05-01
Series:Advanced Science
Subjects:
brain tumor
immunoadjuvant
immunotherapy
polymersomes
targeted delivery
Online Access:https://doi.org/10.1002/advs.202103689

Similar Items

Similar Items